Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report
Cancer Chemotherapy and Pharmacology · 2026
DOI: 10.1007/s00280-026-04975-w ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2026. Verfasst von Hishan Tharmaseelan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düs…. Hauptthemen laut MEDLINE: Hodgkin Disease, Jaundice, Chronic Idiopathic, ATP-Binding Cassette, Sub-Family C Proteins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Dubin-Johnson syndrome (DJS) results from ABCC2/MRP2 mutations causing impaired biliary transport. MRP2 also mediates hepatic elimination of chemotherapeutic agents, yet no data exist on anthracycline-based chemotherapy in adult DJS patients. We report a 26-year-old male with advanced-stage classic Hodgkin lymphoma and DJS harboring a novel homozygous ABCC2 variant (c.2291G>A, p.Gly764Asp). After a pembrolizumab prephase, full-dose BrECADD was administered, and samples were taken for therapeutic drug monitoring (TDM), which demonstrated normal etoposide and doxorubicin pharmacokinetics. Complete metabolic remission was achieved without significant toxicity. This case demonstrates that TDM-guided, full-dose anthracycline-based chemotherapy is feasible in DJS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, and Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), University of C…
- Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK.
- Institute of Human Genetics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- Clinical Pharmacology, Department I of Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Zitieren
APA
Tharmaseelan, H., Jaworek, C. P., Borchmann, P., Voltin, C. A., Galler, M., Veal, G. J., Lepkes, L., Reusch, B., Velmans, C., Netzer, C., Yang, W., Fuhr, U., & Barnett, S. (2026). Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-026-04975-w
Vancouver
Tharmaseelan H, Jaworek CP, Borchmann P, Voltin CA, Galler M, Veal GJ, et al. Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report. Cancer Chemotherapy and Pharmacology. 2026. doi:10.1007/s00280-026-04975-w
BibTeX
@article{Tharmaseelan2026,
author = {Tharmaseelan, Hishan and Jaworek, Christian Peter and Borchmann, Peter and Voltin, Conrad-Amadeus and Galler, Martin and Veal, Gareth J and Lepkes, Louisa and Reusch, Björn and Velmans, Clara and Netzer, Christian and Yang, Wenyu and Fuhr, Uwe and Barnett, Shelby},
title = {Successful treatment with BrECADD in a patient with Dubin-Johnson syndrome and classic Hodgkin lymphoma: a case report},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
doi = {10.1007/s00280-026-04975-w}
}
EUVIMED